Evidence map›Paper›PMID 27171673›Full record

ReviewJournal of gynecologic oncology2016

Advances in diagnosis and treatment of metastatic cervical cancer.

Haoran Li, Xiaohua Wu, Xi Cheng

Registry-linked trialOpen access · diamondAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Journal of gynecologic oncology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06101966 (A Novel Predictive Model and Risk Stratification for Early Metastasis in Cervical Cancer Patients After Radiotherapy), which is not on this map. Cited by 292 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
292citing papers in PubMed, 4 pooled it
21.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT06101966 not yet recruitingnot on this mapstarted 2023, after this paper: background citation

A Novel Predictive Model and Risk Stratification for Early Metastasis in Cervical Cancer Patients After Radiotherapy

TypeobservationalSponsorFujian Cancer HospitalRan2023 to 2027Enrolled500ConditionsCervical Cancer, Radiotherapy, Distant Metastasis, Prognostic ModelArmsexternal pelvic beam radiotherapy (EBRT) followed by individualized high-dose-rate intracavitary brachytherapy (HDR-ICBT)
3 · Its place in the literature

Who cites it

292 citing papers in PubMed, 4 syntheses or guidelines pooled it, 524 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Review
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Review
  20. Article

232 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Haoran LiDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-7046-9379
Xiaohua WuDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China.ORCID http://orcid.org/0000-0002-8213-3119
Xi ChengDepartment of Gynecological Oncology, Fudan University Shanghai Cancer Center, Shanghai, China. chengxi_1@hotmail.com.ORCID http://orcid.org/0000-0002-5685-4588
Fudan University Shanghai Cancer Center · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Cervical cancer is one of the most common cancers in women worldwide. The outcome of patients with metastatic cervical cancer is poor. We reviewed the relevant literature concerning the treatment and diagnosis of metastatic cervical cancer. There are two types of metastasis related to different treatments and survival rates: hematogenous metastasis and lymphatic metastasis. Patients with hematogenous metastasis have a higher risk of death than those with lymphatic metastasis. In terms of diagnosis, fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) and PET-computed tomography are effective tools for the evaluation of distant metastasis. Concurrent chemoradiotherapy and subsequent chemotherapy are well-tolerated and efficient for lymphatic metastasis. As for lung metastasis, chemotherapy and/or surgery are valuable treatments for resistant, recurrent metastatic cervical cancer and chemoradiotherapy may be the optimal choice for stage IVB cervical cancer. Chemotherapy and bone irradiation are promising for bone metastasis. A better survival is achieved with multimodal therapy. Craniotomy or stereotactic radiosurgery is an optimal choice combined with radiotherapy for solitary brain metastases. Chemotherapy and palliative brain radiation may be considered for multiple brain metastases and other organ metastases.

Indexed as

Bone NeoplasmsBrain NeoplasmsChemoradiotherapyFemaleFluorodeoxyglucose F18HumansLung NeoplasmsLymphatic MetastasisPositron-Emission TomographyUterine Cervical NeoplasmsFluorodeoxyglucose F18DiagnosisNeoplasm MetastasisTherapeuticsUterine Cervical Neoplasms

Identifiers

PMID27171673
PMCPMC4864519
OpenAlexW2370300800

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.